Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

MD-224 is a proteolysis-targeting chimera (PROTAC) that contains the murine double minute 2 (MDM2) inhibitor MI-1242 conjugated to lenalidomide (Item No. 14643).1 It induces degradation of MDM2, which increases p53 levels, in RS4;11 acute lymphoblastic leukemia (ALL) cells when used at a concentration of 10 nM. MD-224 also inhibits the growth of RS4;11 cells (IC50 = 1.5 nM). In vivo, MD-224 (50 mg/kg every other day for three weeks) induces complete tumor regression and does not affect body weight in an RS4;11 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Discovery of MD-